DrugPatentWatch Database Preview
Patent: 8,216,997
» See Plans and Pricing
Summary for Patent: 8,216,997
| Title: | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| Abstract: | In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. |
| Inventor(s): | Seehra; Jasbir (Lexington, MA), Pearsall; Robert Scott (Woburn, MA), Kumar; Ravindra (Acton, MA) |
| Assignee: | Acceleron Pharma, Inc. (Cambridge, MA) |
| Application Number: | 12/856,420 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,216,997
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | ARANESP | darbepoetin alfa | VIAL; SUBCUTANEOUS | 103951 | 010 | 2001-09-17 | Start Trial | Acceleron Pharma, Inc. (Cambridge, MA) | 2029-08-13 | RX | search | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; SUBCUTANEOUS | 103951 | 009 | 2001-09-17 | Start Trial | Acceleron Pharma, Inc. (Cambridge, MA) | 2029-08-13 | RX | search | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; SUBCUTANEOUS | 103951 | 008 | 2001-09-17 | Start Trial | Acceleron Pharma, Inc. (Cambridge, MA) | 2029-08-13 | RX | search | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; SUBCUTANEOUS | 103951 | 007 | 2001-09-17 | Start Trial | Acceleron Pharma, Inc. (Cambridge, MA) | 2029-08-13 | RX | search | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; SUBCUTANEOUS | 103951 | 006 | 2001-09-17 | Start Trial | Acceleron Pharma, Inc. (Cambridge, MA) | 2029-08-13 | RX | search | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 005 | 2001-09-17 | Start Trial | Acceleron Pharma, Inc. (Cambridge, MA) | 2029-08-13 | RX | search | |
| Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 004 | 2001-09-17 | Start Trial | Acceleron Pharma, Inc. (Cambridge, MA) | 2029-08-13 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,216,997
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2010019261 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2011020045 | Start Trial |
| United States of America | 10131700 | Start Trial |
| United States of America | 10377996 | Start Trial |
| United States of America | 10689427 | Start Trial |
| United States of America | 10829532 | Start Trial |
| United States of America | 10829533 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
